Definium’s oral LSD candidate DT120 shows strong anxiety reduction in Phase 3 trial

Definium Therapeutics reported that its single‑dose oral LSD candidate DT120 achieved a statistically significant reduction in anxiety symptoms in a Phase 3 study of generalized anxiety disorder. The 12‑week trial enrolled 214 adults and met both its primary and key secondary efficacy endpoints.

Participants receiving DT120 experienced a placebo‑adjusted drop of 5.4 points on a clinician‑administered anxiety scale, exceeding the 5‑point improvement analysts had projected. The result was described by Jefferies as one of the strongest efficacy benefits seen in the indication.

The positive readout follows a earlier Phase 3 success for DT120 in major depressive disorder reported in June, reinforcing the company’s momentum in psychedelic therapeutics.